Recently approved and future treatment options for immunoglobulin A nephropathy
| Drugs | Status | |
|---|---|---|
| Recent approvals | Endothelin and angiotensin receptor antagonist: sparsentan24 Endothelin receptor antagonist: atrasentan25 Corticosteroid: targeted-release formulation budesonide30 Complement inhibitor: iptacopan32,38 | Full approval Accelerated approval Full approval Accelerated |
| Future (not approved) treatment options | Complement inhibitors33–35,37,39,40 | |
| Avacopan, ravulizumab, cemdisiran, vemircopan, pegcetacoplan IONIS-Fb-LRx Narsoplimab RO7434656 ARO-C3 | Phase 2 and 3 trials in progress Phase 3 trial in progress Phase 3 negative trial Phase 3 trial in progress Phase 1 trial in progress | |
| B-cell–depleting therapies41–45 | ||
| Atacicept Sibeprenlimab, zigakibart, telitacicept | Phase 3 trial in progress Phase 2 and 3 trials in progress | |
| Plasma cell inhibitors46,47 | ||
| Felzartamab, mezagitamab, bortezomib | Phase 2 trials in progress |